Ausel, Inc.
About Ausel, Inc.
Ausel, Inc. specializes in cancer biomarker assessment through accurate, easy, and early detection services. The company advances biomarker detection with a non-invasive saliva test prioritizing simplicity and accessibility. Clinical trials have confirmed the effectiveness of its Heliora test in identifying 14 types of cancer, including pancreatic and glioblastoma. It operates as a privately held biotechnology research company headquartered in Carlsbad, California.
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Raised $120,000 through private placement in biotechnology.
- Developing non-invasive saliva test shown effective for 14 cancer types in trials.
- Founded in 2021 with headquarters in Carlsbad, CA and three employees.
- Leadership includes Founder & CEO Nick Ainslie and Co-Founder & COO Paul Shockley.
Ask StreetZero about Ausel, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account